Eosinophilic Disorders Market - 2023-2031
The Eosinophilic Disorders Market was valued at US$ 150 million in 2023 and is anticipated to reach US$ 278 million by 2031, at a CAGR of 0.071 from 2026 to 2032.
The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Eosinophilic Disorders Market.
This report delivers a comprehensive overview of the Eosinophilic Disorders Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Eosinophilic Disorders Market. The Eosinophilic Disorders Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2023–2031.
Eosinophilic Disorders Market Scope:
By Type
This report delivers a comprehensive overview of the Eosinophilic Disorders Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Eosinophilic Disorders Market. The Eosinophilic Disorders Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2023–2031.
This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Regional Analysis:
The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Eosinophilic Disorders Market.
This report delivers a comprehensive overview of the Eosinophilic Disorders Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Eosinophilic Disorders Market. The Eosinophilic Disorders Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2023–2031.
Eosinophilic Disorders Market Scope:
By Type
- Eosinophilic Esophagitis
- Eosinophilic Gastritis
- Eosinophilic Enteritis
- Eosinophilic Colitis
- Hypereosinophilic Syndrome
- Medications
- Dietary Therapy
- Dilation
- Others
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
- Novartis A.G
- GlaxoSmithKline Plc.
- Teva Pharmaceutical
- Pfizer Inc.
- AstraZeneca
- Sanofi S.A
- Curia
- LGM Pharma
- Henan Lihua Pharmaceuticals Ltd.
- Hikma Pharmaceuticals
This report delivers a comprehensive overview of the Eosinophilic Disorders Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Eosinophilic Disorders Market. The Eosinophilic Disorders Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2023–2031.
This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Regional Analysis:
- North America (U.S., Canada, Mexico)
- Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
- Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
- South America (Colombia, Brazil, Argentina, Rest of South America)
- Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
- Increase Your Customer Base by 3X using our Partner Identification tool
- Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.
- Identify high potential M&A targets based on synergies, market positioning and growth trajectory.
- Prioritize partners by strategic fit rather than general capability.
- Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.
- Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.
- White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.
- Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.
- Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.
- Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
1. METHODOLOGY AND SCOPE
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. DEFINITION AND OVERVIEW
3. EXECUTIVE SUMMARY
3.1. Snippet by Type
3.2. Snippet by Treatment
3.3. Snippet by Distribution Channels
3.4. Snippet by Region
4. DYNAMICS
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing Research & Developments and Approvals of New and Innovative Drugs
4.1.1.2. Increasing Prevalence of Eosinophilic Disorders
4.1.2. Restraints
4.1.2.1. High Cost of the Treatment
4.1.3. Opportunity
4.1.4. Impact Analysis
5. INDUSTRY ANALYSIS
5.1. Porter’s 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Unmet Needs
5.4. Regulatory Analysis
5.5. Russia-Ukraine War Impact Analysis
5.6. DMI Opinion
6. BY TYPE
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
6.1.2. Market Attractiveness Index, By Type
6.2. Eosinophilic Esophagitis
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Eosinophilic Gastritis
6.4. Eosinophilic Enteritis
6.5. Eosinophilic Colitis
6.6. Hypereosinophilic Syndrome
7. BY TREATMENT
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
7.1.2. Market Attractiveness Index, By Treatment
7.2. Medications
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.2.2.1. Mepolizumab
7.2.2.2. Reslizumab
7.2.2.3. Benralizumab
7.2.2.4. Dupilunab
7.2.2.5. Omalizumab
7.2.2.6. Imatinib
7.2.2.7. Others
7.3. Dietary Therapy
7.4. Dilation
7.5. Others
8. BY DISTRIBUTION CHANNEL
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
8.1.2. Market Attractiveness Index, By Distribution Channel
8.2. Hospital Pharmacy
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Retail Pharmacy
8.4. Online Pharmacy
8.5. Others
9. BY REGION
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
9.1.2. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key Region-Specific Dynamics
9.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
9.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
9.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
9.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
9.2.6.1. U.S.
9.2.6.2. Canada
9.2.6.3. Mexico
9.3. Europe
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
9.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
9.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
9.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
9.3.6.1. Germany
9.3.6.2. U.K.
9.3.6.3. France
9.3.6.4. Italy
9.3.6.5. Spain
9.3.6.6. Rest of Europe
9.4. South America
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
9.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
9.4.6.1. Brazil
9.4.6.2. Argentina
9.4.6.3. Rest of South America
9.5. Asia Pacific
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
9.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
9.5.6.1. China
9.5.6.2. India
9.5.6.3. Japan
9.5.6.4. South Korea
9.5.6.5. Rest of Asia Pacific
9.6. Middle East and Africa
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
9.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
10. COMPETITIVE LANDSCAPE
10.1. Competitive Scenario
10.2. Product Benchmarking
10.3. Company Share Analysis
10.4. Key Developments and Strategies
11. COMPANY PROFILES
11.1. Novartis A.G *
11.1.1. Company Overview
11.1.2. Product Portfolio and Description
11.1.3. Financial Overview
11.1.4. Key Developments
11.2. GlaxoSmithKline Plc.
11.3. Teva Pharmaceutical
11.4. Pfizer Inc.
11.5. AstraZeneca
11.6. Sanofi S.A
11.7. Curia
11.8. LGM Pharma
11.9. Henan Lihua Pharmaceuticals Ltd.
11.10. Hikma Pharmaceuticals (LIST NOT EXHAUSTIVE)
12. APPENDIX
12.1. About Us and Services
12.2. Contact Us
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. DEFINITION AND OVERVIEW
3. EXECUTIVE SUMMARY
3.1. Snippet by Type
3.2. Snippet by Treatment
3.3. Snippet by Distribution Channels
3.4. Snippet by Region
4. DYNAMICS
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing Research & Developments and Approvals of New and Innovative Drugs
4.1.1.2. Increasing Prevalence of Eosinophilic Disorders
4.1.2. Restraints
4.1.2.1. High Cost of the Treatment
4.1.3. Opportunity
4.1.4. Impact Analysis
5. INDUSTRY ANALYSIS
5.1. Porter’s 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Unmet Needs
5.4. Regulatory Analysis
5.5. Russia-Ukraine War Impact Analysis
5.6. DMI Opinion
6. BY TYPE
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
6.1.2. Market Attractiveness Index, By Type
6.2. Eosinophilic Esophagitis
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Eosinophilic Gastritis
6.4. Eosinophilic Enteritis
6.5. Eosinophilic Colitis
6.6. Hypereosinophilic Syndrome
7. BY TREATMENT
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
7.1.2. Market Attractiveness Index, By Treatment
7.2. Medications
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.2.2.1. Mepolizumab
7.2.2.2. Reslizumab
7.2.2.3. Benralizumab
7.2.2.4. Dupilunab
7.2.2.5. Omalizumab
7.2.2.6. Imatinib
7.2.2.7. Others
7.3. Dietary Therapy
7.4. Dilation
7.5. Others
8. BY DISTRIBUTION CHANNEL
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
8.1.2. Market Attractiveness Index, By Distribution Channel
8.2. Hospital Pharmacy
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Retail Pharmacy
8.4. Online Pharmacy
8.5. Others
9. BY REGION
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
9.1.2. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key Region-Specific Dynamics
9.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
9.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
9.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
9.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
9.2.6.1. U.S.
9.2.6.2. Canada
9.2.6.3. Mexico
9.3. Europe
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
9.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
9.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
9.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
9.3.6.1. Germany
9.3.6.2. U.K.
9.3.6.3. France
9.3.6.4. Italy
9.3.6.5. Spain
9.3.6.6. Rest of Europe
9.4. South America
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
9.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
9.4.6.1. Brazil
9.4.6.2. Argentina
9.4.6.3. Rest of South America
9.5. Asia Pacific
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
9.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
9.5.6.1. China
9.5.6.2. India
9.5.6.3. Japan
9.5.6.4. South Korea
9.5.6.5. Rest of Asia Pacific
9.6. Middle East and Africa
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
9.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
10. COMPETITIVE LANDSCAPE
10.1. Competitive Scenario
10.2. Product Benchmarking
10.3. Company Share Analysis
10.4. Key Developments and Strategies
11. COMPANY PROFILES
11.1. Novartis A.G *
11.1.1. Company Overview
11.1.2. Product Portfolio and Description
11.1.3. Financial Overview
11.1.4. Key Developments
11.2. GlaxoSmithKline Plc.
11.3. Teva Pharmaceutical
11.4. Pfizer Inc.
11.5. AstraZeneca
11.6. Sanofi S.A
11.7. Curia
11.8. LGM Pharma
11.9. Henan Lihua Pharmaceuticals Ltd.
11.10. Hikma Pharmaceuticals (LIST NOT EXHAUSTIVE)
12. APPENDIX
12.1. About Us and Services
12.2. Contact Us
